Ganaxolone, marketed under the brand name Ztalmy, is FDA approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in individuals aged 2 years and older.

Pacritinib, with the generic name pacritinib [pak-RI-ti-nib], is approved by the FDA for the treatment of myelofibrosis in adults.

Ciltacabtagene autoleucel received FDA approval on February 28, 2022.

Mitapivat (Pyrukynd) was approved by the FDA on February 17, 2022.

The FDA approved Sutimlimab (Enjaymo) on February 4, 2022. This approval marked an important development for patients with CAD.

Faricimab ophthalmic was approved by the FDA on January 28, 2022. This approval covers its use in adults for treating neovascular age-related macular degeneration and diabetic macular edema.

Tebentafusp received FDA approval on January 25, 2022. It is a prescription medication used to treat adults with uveal melanoma.

Daridorexant was approved by the U.S. Food and Drug Administration (FDA) on January 7, 2022, for the treatment of insomnia in adults who have difficulty falling asleep or staying asleep.

The FDA approved Recorlev on December 30, 2021, for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome when surgery is not an option or has not been curative.

The FDA first approved Gilenya (fingolimod) on September 21, 2010, for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The FDA granted approval for Tezspire on December 17, 2021, as an add-on maintenance treatment for severe asthma.

The combination of these two drugs was approved by the FDA to treat signs and symptoms of BPH, providing relief for men with an enlarged prostate.